Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

David Filmore

Executive Editor

Rochester, NY
David Filmore has been covering the health care sector as a writer and editor for 16 years. He specializes in devices and diagnostics, particularly focusing on the regulatory and reimbursement dynamics that impact a company’s ability to succeed in the marketplace. Originally trained as a scientist, Dave enjoys dissecting technical topics to reach a core understanding. As a writer and editor, he relishes communicating that understanding, important context and key takeaways for practical use by the reader. Dave has led operations or served on the staff of “The Gray Sheet” for more than a decade, and now oversees Regulatory and Policy content for the new Medtech Insight. Previously, he was an editor with the American Chemical Society, producing content for professionals in the pharmaceutical industry and analytical instrumentation space. He has also worked in the pharma industry, and has a degree in chemistry. Dave lives with his wife and two kids in Rochester, NY.
Advertisement
Set Alert for Articles By David Filmore

Latest From David Filmore

Device-Tax Repeal Opportunity Slips Away As GOP Pulls Health Bill From Consideration

The House Republican conference decision to pull the American Health Care Act from consideration means repeal of the medical device tax has died, at least in the short term. After hours of debate on the floor, and failing to gather enough votes to pass the bill, House Speaker Paul Ryan and President Trump called a halt to the Affordable Care Act repeal effort, saying they will now focus on other objectives, such as tax reform.

Policy Legislation

Diagnostics Reg Overhaul Floated In US House

Lawmakers are circulating draft legislation that would create a new regulatory category, distinct from medical devices, combining in vitro diagnostics and laboratory-developed tests. The representatives say they don't have specific timing in mind for moving the bill forward. But it is being circulated just as the FDA user-fee reauthorization process is getting off the ground, presenting a possible legislative vehicle.

In Vitro Diagnostics FDA

Symetis Seeks $60m IPO To Make A Splash In Structural Heart

Symetis, Europe's No. 4 in the TAVR market, hopes its initial public offering, with a price range of €26 to €32 per share on Euronext Paris, will help build on its recent transcatheter mitral valve repair acquisition and its growing market position in TAVR.

Cardiology Financing

Classified: Next-Gen Sequencing Analyzers, Mobile Glucose Monitoring, Restless-Leg Devices

FDA issued orders officially finalizing regulatory classifications and special controls for next-generation sequencing analyzers; "secondary display" devices for continuous glucose monitor data; and vibratory counter-stimulation devices for restless leg syndrome. And the agency is working towards formalizing 510(k) exemptions for future devices of these types as well.

Diabetic Care In Vitro Diagnostics

Trump Budget: FDA-Regulated Firms Should Pay 'Their Share' In User Fees

President Trump's initial budget plan for US FDA would, it appears, make industry-paid user fees a much larger proportion of the agency's budget, but details are lacking. As is, the plan could complicate agreements that came out of FDA-industry user-fee negotiations last summer, but observers say this is just the first step in a process and Congress will ultimately decide. Trump would also shave 22% from the National Institutes of Health.

Policy Legislation

Gottlieb At FDA: Industry Will Look For User-Fee Deal Support, Restrained Regulations

After months of waiting on whether President Trump would pick a conventional FDA commissioner candidate or go off the beaten path, the White House appears to be taking the former approach. Trump is expected to nominate Scott Gottlieb, a George W. Bush administration FDA alum, physician and long-time conservative voice on health policy. Gottlieb will favor reduced regulatory burdens, and industry hopes he will help push forward a device user-fee reauthorization agreement.

Regulation FDA
See All
Advertisement
UsernamePublicRestriction

Register